<DOC>
	<DOCNO>NCT02366208</DOCNO>
	<brief_summary>This trial ass efficacy safety Polyethylene Glycol thymosin alpha1 ( PEG-Tα1 ) , new long immunomodulator ( Category 1.1 Chemical Drugs ) develop Hansoh Pharmaceutical China , combination adefovir HBeAg-positive patient chronic hepatitis B .</brief_summary>
	<brief_title>Phase II Trial Combination Treatment PEG-Tα1 Adefovir HBeAg Positive Chronic Hepatitis B</brief_title>
	<detailed_description>A total 116 HBeAg-positive patient recruit 12 hospital China , randomize two group . The combination group ( n= 57 ) receive PEG-Tα1 ( 1.6 mg/ml , week , take subcutaneously ) adefovir ( 10 mg , daily , take orally ) 24 week . The control group ( n = 59 ) receive placebo adefovir . Both group receive adefovir continuously additional 24 week . The primary endpoint loss HBeAg 48 week . The secondary endpoint include 1 ) loss hepatitis B virus ( HBV ) DNA , 2 ) HBeAg seroconversion 3 ) alanine aminotransferase ( ALT ) normalization etc . week 4 , 12 , 24 , 36 48 . The number CD4＋and CD8＋T cell also determine 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>Chronic hepatitis B 6 month ALT ＞ 2 × Upper Limit Normal ( ULN ) Serum bilirubin ＜ 2 × ULN . Positive HBeAg HBVDNA 1.00E＋05 IU/ml 9.99E＋09 IU/ml . Informed Consent Form ( ICF ) sign . Hepatitis A , C , D , E HIV infection . Autoimmune hepatitis . Hepatic cirrhosis . Serum creatinine ＞ 1.5 × ULN Ccr ＜ 50 ml/min , Haemoglobin ＜ 110g/L ( male ) ＜ 100g/L ( female ) , Platelet＜ 80 E＋09/L , Serum albumin ≤ 32g/L , Serum albumin/globulin ( A/G ) ≤0.9 , Neutrophile granulocyte ＜ 1.0 E＋09/L , Prothrombin time＞ULN＋3 second , Cholinesterase＜2500U/L . Hepatitic carcinoma Alpha Fetal Protein ( AFP ) ＞ 100ng/ml Patients severe disease combine , could affect therapy . Patients accept clinical trial within 6 month first administrate . Patients accept immunomodulating antiviral treatment within 6 month trial . Patients autoimmune disease . Thymosin allergy . Pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Polyethylene Glycol Thymosin alpha1</keyword>
	<keyword>Adefovir</keyword>
	<keyword>Hepatitis B e Antigens positive</keyword>
</DOC>